Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 23;20(1):17.
doi: 10.1186/s12931-019-0984-3.

Effectiveness of long-term using statins in COPD - a network meta-analysis

Yongbin Lu  1 , Ruixia Chang  2 , Jia Yao  1 , Xinni Xu  1 , Yongjun Teng  1 , Ning Cheng  3
Affiliations
Review

Effectiveness of long-term using statins in COPD - a network meta-analysis

Yongbin Lu et al. Respir Res. .

Abstract

Objectives: To evaluate the effectiveness of long-term treatment of statins for chronic obstructive pulmonary disease (COPD), and to answer which one is better.

Methods: General meta-analysis was performed to produce polled estimates of the effect of mortality, inflammatory factors, and lung function index in COPD patients by the search of PubMed, Web of Science, Embase, and China National Knowledge Infrastructure for eligible studies. A network meta-analysis was performed to synthetically compare the effectiveness of using different statins in COPD patients.

Results: General meta-analysis showed that using statins reduced the risk of all-cause mortality, heart disease-related mortality and COPD acute exacerbation (AECOPD) in COPD patients, the RR (95% CI) were 0.72 (0.63,0.84), 0.72 (0.53,0.98) and 0.84 (0.79,0.89), respectively. And using statins reduced C-reactive protein (CRP) and pulmonary hypertension (PH) in COPD patients, the SMD (95% CI) were - 0.62 (- 0.52,-0.72) and - 0.71 (- 0.85,-0.57), respectively. Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Fluvastatin (76.0%) and Atorvastatin (75.4%) had higher cumulative probability than other satins in reducing PH in COPD patients.

Conclusions: Using statins can reduce the risk of mortality, the level of CRP and PH in COPD patients. In addition, Fluvastatin and Atorvastatin are more effective in reducing CRP and PH in COPD patients.

Keywords: CRP; Mortality; Network meta-analysis; PH; Statins.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Forest plot showing effect of statins on all-cause mortality in COPD patients
Fig. 2
Fig. 2
Forest plot showing effect of statins on CRP in COPD patients
Fig. 3
Fig. 3
Evidence network of the effect of using statins on CRP levels in COPD patients
Fig. 4
Fig. 4
Rank probability analysis of CRP with using statins in COPD patients
Fig. 5
Fig. 5
Forest plot showing effect of statins on PH in COPD patients
Fig. 6
Fig. 6
Evidence network of the effect of using statins on PH levels in COPD patients
Fig. 7
Fig. 7
Rank probability analysis of PH with using statins in COPD patients
See this image and copyright information in PMC

References

    1. Marin L, Colombo P, Bebawy M, Young PM, Traini D. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opinion on Drug Delivery. 2011;8:1205. doi: 10.1517/17425247.2011.588697. - DOI - PubMed
    1. Adeloye D, Chua S, Chinwei L, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5:020415. doi: 10.7189/jogh.05.020415. - DOI - PMC - PubMed
    1. Chen W, Thomas J, Sadatsafavi M, Fitzgerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respiratory Medicine. 2015;3:631–639. doi: 10.1016/S2213-2600(15)00241-6. - DOI - PubMed
    1. Curkendall SM, Deluise C, Jones JK, Lanes S, Stang MR, Jr GE, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Annals of Epidemiology. 2006;16:63. doi: 10.1016/j.annepidem.2005.04.008. - DOI - PubMed
    1. Javad MSA, Hanieh R, Masoomeh F, Rostam Y, Mansour E. Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: a randomized controlled trial. Iran Red Crescent Med J. 2013;15:649–654. doi: 10.5812/ircmj.8267. - DOI - PMC - PubMed

MeSH terms